• Nuvation Bio highlighted IBTROZI (taletrectinib) as a commercial driver, with U.S. net product revenue of USD 43 million as of March 31, 2026.
• IBTROZI is marketed for advanced ROS1+ NSCLC in the U.S., Japan, China; EMA validated its marketing authorisation application.
• Pro forma cash balance pegged at about USD 736 million, positioned as sufficient to reach profitability without additional funding.
• Safusidenib positioned as a brain-penetrant IDH1 inhibitor, with a pivotal SIGMA study enrolling in IDH1-mutant glioma.
• Drug-Drug Conjugate platform remains preclinical, with candidates designed to bind two targets simultaneously.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief on July 20, 2026, and is solely responsible for the information contained therein.